BIOMAT Database Logo BIOMAT Database Logo

Levodopa withdrawal and the neuroleptic malignant syndrome. 1986

R Sandyk, and R P Iacono

UI MeSH Term Description Entries
D007980 Levodopa The naturally occurring form of DIHYDROXYPHENYLALANINE and the immediate precursor of DOPAMINE. Unlike dopamine itself, it can be taken orally and crosses the blood-brain barrier. It is rapidly taken up by dopaminergic neurons and converted to DOPAMINE. It is used for the treatment of PARKINSONIAN DISORDERS and is usually given with agents that inhibit its conversion to dopamine outside of the central nervous system. L-Dopa,3-Hydroxy-L-tyrosine,Dopaflex,Dopar,L-3,4-Dihydroxyphenylalanine,Larodopa,Levopa,3 Hydroxy L tyrosine,L 3,4 Dihydroxyphenylalanine,L Dopa
D009459 Neuroleptic Malignant Syndrome A potentially fatal syndrome associated primarily with the use of neuroleptic agents (see ANTIPSYCHOTIC AGENTS) which are in turn associated with dopaminergic receptor blockade (see RECEPTORS, DOPAMINE) in the BASAL GANGLIA and HYPOTHALAMUS, and sympathetic dysregulation. Clinical features include diffuse MUSCLE RIGIDITY; TREMOR; high FEVER; diaphoresis; labile blood pressure; cognitive dysfunction; and autonomic disturbances. Serum CPK level elevation and a leukocytosis may also be present. (From Adams et al., Principles of Neurology, 6th ed, p1199; Psychiatr Serv 1998 Sep;49(9):1163-72) Neuroleptic-Induced Neuroleptic Malignant Syndrome,Neuroleptic-Malignant Syndrome, Neuroleptic Induced,NMS (Neuroleptic Malignant Syndrome),NMSs (Neuroleptic Malignant Syndrome),Neuroleptic Induced Neuroleptic Malignant Syndrome,Neuroleptic Malignant Syndrome, Neuroleptic Induced,Neuroleptic Malignant Syndromes,Syndrome, Neuroleptic Malignant,Syndromes, Neuroleptic Malignant
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D013375 Substance Withdrawal Syndrome Physiological and psychological symptoms associated with withdrawal from the use of a drug after prolonged administration or habituation. The concept includes withdrawal from smoking or drinking, as well as withdrawal from an administered drug. Drug Withdrawal Symptoms,Withdrawal Symptoms,Drug Withdrawal Symptom,Substance Withdrawal Syndromes,Symptom, Drug Withdrawal,Symptom, Withdrawal,Symptoms, Drug Withdrawal,Symptoms, Withdrawal,Syndrome, Substance Withdrawal,Syndromes, Substance Withdrawal,Withdrawal Symptom,Withdrawal Symptom, Drug,Withdrawal Symptoms, Drug,Withdrawal Syndrome, Substance,Withdrawal Syndromes, Substance

Related Publications

R Sandyk, and R P Iacono
Neuroleptic malignant syndrome complicating levodopa withdrawal.
July 1991, The Medical journal of Australia,
R Sandyk, and R P Iacono
[Neuroleptic malignant-like syndrome following levodopa withdrawal].
January 1990, Revue neurologique,
R Sandyk, and R P Iacono
Neuroleptic malignant syndrome without withdrawal of levodopa.
January 2009, The National medical journal of India,
R Sandyk, and R P Iacono
Levodopa withdrawal syndrome identical to neuroleptic malignant syndrome.
January 1986, Postgraduate medical journal,
R Sandyk, and R P Iacono
Neuroleptic malignant syndrome. When levodopa withdrawal is the cause.
April 1991, Postgraduate medicine,
R Sandyk, and R P Iacono
Neuroleptic malignant syndrome postoperative onset due to levodopa withdrawal.
December 1995, Journal of clinical anesthesia,
R Sandyk, and R P Iacono
Successful treatment of levodopa-induced myoclonus and levodopa withdrawal-induced neuroleptic malignant syndrome. A case report.
June 1988, Clinical neuropharmacology,
R Sandyk, and R P Iacono
Neuroleptic malignant syndrome (NMS) on neuroleptic withdrawal.
September 1990, Acta psychiatrica Scandinavica,
R Sandyk, and R P Iacono
Withdrawal-induced neuroleptic malignant syndrome.
March 1994, The American journal of psychiatry,
R Sandyk, and R P Iacono
Neuroleptic malignant syndrome and amantadine withdrawal.
January 1985, The American journal of psychiatry,
Copied contents to your clipboard!